With Phase 3 Duchenne success, Capricor plots path forward after FDA rejection
With Phase 3 Duchenne success, Capricor plots path forward after FDA rejection
本文は利用できません。元の情報源をご確認ください。
With Phase 3 Duchenne success, Capricor plots path forward after FDA rejection
A compact weekly email covering company moves, product signals, regulatory updates, and notable funding.